



^{18}F -Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617

Frederik L. Giesel¹ · Jens Cardinale² · Martin Schäfer² · Oliver Neels² · Martina Benešová² · Walter Mier¹ · Uwe Haberkorn¹ · Klaus Kopka² · Clemens Kratochwil¹ 

Received: 2 May 2016 / Accepted: 14 June 2016 / Published online: 25 June 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

The biochemical and radiological responses to radionuclide therapy with ^{177}Lu -PSMA-617 targeting prostate-specific membrane antigen (PSMA) make it a promising approach to the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) [1]. However, PSMA-617 has been reported to have slower tumour accumulation and clearance kinetics than PSMA-11, and the latter is still therefore the preferred diagnostic agent when labelled with generator-produced ^{68}Ga which has a short half-life (68 min) [2]. A PSMA-targeting ^{18}F -labelled PET tracer could be produced with higher activity in a cyclotron and the half-life (110 min) would allow both late imaging beyond 1 h after injection and shipping to satellite institutions. However, the structure of the currently most-used ^{18}F -labelled PSMA tracer, ^{18}F -DCFPyl, is different from that of PSMA-617, and like PSMA-11 it might be a sub-optimal surrogate for stratifying patients according to their suitability for therapy with ^{177}Lu -PSMA-617 [3].

Based on the scaffold of PSMA-617, the novel compound ^{18}F -PSMA-1007 was developed. As shown in the image (a, d), PSMA-1007 shares the Glu-urea-Lys motif targeting the catalytic domain of PSMA and the naphthalene-based linker region considered to cotarget the hydrophobic accessory pocket [4], while in the radiolabel-bearing moiety glutamic acids were



added to mimic the carboxylic acid groups of the DOTA chelator to retain the polar charge influencing clearance kinetics.

The image also shows a patient with mCRPC who was staged using ^{18}F -PSMA-1007 (b PET 1 h after injection, maximum intensity projection) and treatment with ^{177}Lu -PSMA-617 (c planar scan 24 h after injection, geometric mean). In analogy to the chemical structure, the uptake in tumour and normal organs is very similar with the two compounds.

Thus, ^{18}F -PSMA-1007 and ^{177}Lu -PSMA-617 seem to be a perfect theragnostic tandem. Due to the preferred physical characteristics of ^{18}F for PET imaging and the possibility for large-scale production in a cyclotron, ^{18}F -PSMA-1007 is also a promising alternative to ^{68}Ga -PSMA-11 for diagnostic purposes. However, non-inferior diagnostic accuracy has still to be proven in a larger cohort.

✉ Clemens Kratochwil
clemens.kratochwil@med.uni-heidelberg.de

¹ Department for Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120 Heidelberg, Germany

² Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany

Compliance with ethical standards

Ethical approval As this is a retrospective case report of a patient in regular clinical care but not a clinical trial, ethical approval was not needed.

Informed consent Written informed consent for imaging with an experimental tracer and publication of the individual patient history was obtained.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. *J Nucl Med*. 2016. doi:10.2967/jnumed.115.171397.
2. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. *J Nucl Med*. 2015;56(11):1697–705. doi:10.2967/jnumed.115.161299.
3. Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. *Mol Imaging Biol*. 2015;17(4):565–74. doi:10.1007/s11307-015-0850-8.
4. Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. *J Med Chem*. 2008;51:7737–43.

¹⁸F-PSMA-1007 is the subject of a patent application (EP 15 002 800.9, DKFZ)